Cargando…

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed, the hematological benefit during eculizumab t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Risitano, Antonio M., Marotta, Serena, Ricci, Patrizia, Marano, Luana, Frieri, Camilla, Cacace, Fabiana, Sica, Michela, Kulasekararaj, Austin, Calado, Rodrigo T., Scheinberg, Phillip, Notaro, Rosario, Peffault de Latour, Regis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587878/ https://www.ncbi.nlm.nih.gov/pubmed/31258525 http://dx.doi.org/10.3389/fimmu.2019.01157

Ejemplares similares

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
por: Risitano, Antonio M., et al.
Publicado: (2020)

The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target
por: Risitano, Antonio M., et al.
Publicado: (2022)

The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin G., et al.
Publicado: (2022)

Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going
por: Risitano, Antonio M
Publicado: (2014)

Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)

P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS
por: Kulasekararaj, A., et al.
Publicado: (2022)

Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
por: Bektas, Meryem, et al.
Publicado: (2020)

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021)

P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
por: Peffault de Latour, Régis, et al.
Publicado: (2023)

PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: de Latour, Régis Peffault, et al.
Publicado: (2023)

How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future
por: Risitano, Antonio Maria, et al.
Publicado: (2021)

Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report
por: Quinquenel, Anne, et al.
Publicado: (2017)

Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist’s Opinion
por: Gembillo, Guido, et al.
Publicado: (2020)

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
por: Peffault de Latour, Régis, et al.
Publicado: (2020)

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
por: Kim, Jin Seok, et al.
Publicado: (2010)

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA
por: Fishman, Jesse, et al.
Publicado: (2023)

PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin, et al.
Publicado: (2022)

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
por: Brodsky, Robert A., et al.
Publicado: (2020)

P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
por: Szer, Jeff, et al.
Publicado: (2023)

Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)
por: Weisshaar, Kimmo, et al.
Publicado: (2020)

Cerebral Venous Thrombosis in Paroxysmal Nocturnal Hemoglobinuria: A Series of 15 Cases and Review of the Literature
por: Meppiel, Elodie, et al.
Publicado: (2015)

P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA
por: Risitano, A., et al.
Publicado: (2022)

Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies
por: Kulasekararaj, Austin G., et al.
Publicado: (2022)

The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea
por: Kim, Hyerim, et al.
Publicado: (2017)

Myasthenia gravis and paroxysmal nocturnal hemoglobinuria after thymectomy: A rare association
por: Galtier, Jean, et al.
Publicado: (2021)

Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
por: Risitano, Antonio M, et al.
Publicado: (2008)

S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Scheinberg, Phillip, et al.
Publicado: (2023)

Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT
por: Devillier, Raynier, et al.
Publicado: (2023)

P1725: OBSERVATIONAL STUDY TO EVALUATE PATIENT-REPORTED OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Urciuoli, E., et al.
Publicado: (2022)

COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy
por: Barcellini, Wilma, et al.
Publicado: (2020)

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study
por: Schrezenmeier, Hubert, et al.
Publicado: (2020)

Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria
por: Patir, Pusem, et al.
Publicado: (2015)

Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria
por: Mon Père, Nathaniel, et al.
Publicado: (2018)

Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria
por: Ram, R., et al.
Publicado: (2017)

Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria
por: Colden, Melissa A., et al.
Publicado: (2022)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
por: Bravo-Perez, Carlos, et al.
Publicado: (2023)

Early Mortality in Paroxysmal Nocturnal Hemoglobinuria
por: Sørensen, Anne Lykke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0a78j67j67saqpdpqai1n5au36